Latest Patents News

Codeifai Limited reported a near doubling of its half-year loss to $3.93 million, alongside a 32% revenue drop, while pursuing transformative AI and quantum security acquisitions and securing $2.35 million in fresh capital.

ASF Group Limited reports a dramatic turnaround to a $25.8 million profit for FY2025, driven by a one-off $32.7 million gain from subsidiary disposals amid a 70% revenue drop.

Uscom Limited reported a 25% decline in revenue to $3.16 million and a 59% increase in net loss to $3.3 million for FY25, reflecting significant global headwinds. Despite setbacks, the company advanced new product approvals and secured funding to navigate ongoing challenges.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Environmental Clean Technologies Limited reported a $3.52 million net loss for FY2025, marking a modest 5% improvement, while making significant progress in commercialising its COLDry fertiliser technology and securing over $1.7 million in new capital.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Janus Electric Holdings reported a steep 94% rise in net loss to $8.7 million for FY2025, impacted by a disruptive battery recall and significant restructuring costs. The company completed a reverse takeover, raised $8.8 million, and secured a $5 million MOU for African expansion, signaling a bold shift toward heavy transport electrification.

Tissue Repair Ltd reported a 27.3% revenue increase to $3.22 million for FY25, driven by new distribution deals and regulatory progress, while continuing to invest heavily in clinical trials and manufacturing scale-up, resulting in a $4.24 million loss.

Livium Ltd reports a maiden profit at its battery recycling arm Envirostream, advances its lithium extraction joint venture with Mineral Resources, and secures a $30 million grant for its lithium ferro phosphate demonstration plant.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.